Based on this assumption, the use of IL-17/IL-23 immunohistochemical detection could be employed to improve the identification of SS patients with a possible diagnosis in all cases that do not fully meet the American–European criteria for pSS, in particular when the germinal center is not present at histopathological analysis and anti-SSA and anti-SSB antibodies are undetectable in the serum [19]. This evidence concerns the gene IL23A and synovial sarcoma.